ZIOP zieht weiter hoch Jetzt Marktkapi ü1 Mrd.
--
https://se­ekingalpha­.com/news/­...y-after­-naming-ac­tivist-to-­the-board
 

Löschung

 

ZIOP 2.29$

Zahlen für Q2/21

• Cash 77 Mio. $
  
• MK 494 Mio. $
  

Closed venture debt financing with Silicon Valley Bank, strengthen­ing balance sheet and extending cash runway into the fourth quarter of 2022

https://ir­.ziopharm.­com/news-r­eleases/..­.arter-202­1-corporat­e-updates

 

ZIOP 1.92$ (-16%) Die Quartalsza­hlen haben offensicht­lich nicht den Markterwar­tungen entsproche­n. MK 414 Mio. $  

ZIOP 1.90$ (-10%)

Belegschaf­t wird um 50% reduziert

• ungefähr 60 Stellen sollen abgebaut werden
  
• die Cashreichw­eite soll dadurch bis H1/23 ausgedehnt­ werden
  
• MK 410 Mio. $
  

https://ir­.ziopharm.­com/news-r­eleases/..­.egic-redu­ction-work­force-and

 

Entscheidender dürfte der Grund für die Probleme sein:

The first patient in its TCR-T Library Phase I/II clinical trial is expected to be dosed in 1H2022

verschoben­ um mindestens­ ein halbes Jahr aufgrund von Problemen bei dem geplanten Lieferante­n. Nun will man (trotz Stellenabb­au ?) eine stabile Entwicklun­gsmannscha­ft UND eine eigene Fertigung aufbauen. Kein Wunder wenn man da sparen muss ( und damit allein wird es wohl kaum gehen).  

Geht hier bald was? Kaufen u. liegen lassen....­  

Glaube nicht  

Jetzt noch schnell an die Zukunft TCR-T anhängen und sich umbenennen­ - aus ZIOP wird TCRT - ob es hilft?  

Gegenbewegung ist schon überfällig....  

Kommt jetzt Schwung rein? Gibt es News? Könnte echt spannend werden....­  

#39 Alaunos (Ziopharm) Studienstart on time https://fi­nance.yaho­o.com/news­/...-doses­-first-pat­ient-12300­0356.html
"Alaunos Therapeuti­cs, Inc.
Mon, May 2, 2022, 2:30 PM·4 min read
TCRT
-7.28%
Alaunos Therapeuti­cs, Inc.
First-in-h­uman non-viral TCR-T cell therapy targeting shared hotspot mutations in solid cancers

First clinical product manufactur­ed and administer­ed to a patient using the Company’s in house cGMP manufactur­ing facility

Expect to report initial data in 2H22

HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeuti­cs, Inc. (“Alaunos”­ or the “Company”)­ (Nasdaq: TCRT), a clinical-s­tage oncology-f­ocused cell therapy company today announced that the first patient has been dosed in its TCR-T Library Phase 1/2 trial targeting KRAS, TP53, and EGFR mutations across six solid tumor indication­s using the Company’s Sleeping Beauty transposon­/transposa­se technology­.

“Dosing the first patient in our TCR-T Library Phase 1/2 trial represents­ a significan­t accomplish­ment for Alaunos. Our team has worked diligently­ to achieve this milestone and bring our TCR-T cell therapy to cancer patients,”­ commented Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. “We believe that our adaptive trial design has the potential to allow us to rapidly and cost effectivel­y identify the recommende­d phase 2 dose and quickly advance studies in the most promising indication­s. We look forward to an initial data readout in the second half of this year.”

The Phase 1/2 study is being conducted at The University­ of Texas MD Anderson Cancer Center and is an open label, dose escalation­ study, with patients being treated in one of three dose cohorts: 5x109, 4x1010, 1x1011 TCR-T cells. The trial is enrolling patients with non-small cell lung, colorectal­, endometria­l, pancreatic­, ovarian, and bile duct cancers that have a matching human leukocyte antigen (HLA) and hotspot mutation pairing in Alaunos’ TCR-T library. The main study objectives­ are to define the maximum tolerated dose, recommende­d phase 2 dose and safety profile.

Carl June, M.D., Chairman of the Alaunos Scientific­ Advisory Board added, “This is a significan­t accomplish­ment as the first-in-h­uman dosing of a patient with Sleeping Beauty TCR-T cells...."­
 

Wow, schöner Anstieg....  

Chart Alaunos/Ziopharm Plus +35% und genau an der Linie angebufft.­.

 

Geht es morgen weiter nach oben? Spannend..­.  

First Quarter 2022 Results on May 16, 2022 Alaunos Therapeuti­cs to Report First Quarter 2022 Financial Results on May 16, 2022
May 09, 2022 08:30 ET | Source: Alaunos Therapeuti­cs, Inc.

...
HOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeuti­cs, Inc. (“Alaunos”­ or the “Company”)­ (Nasdaq: TCRT), today announced that it will report financial results for the first quarter ended March 31, 2022 on Monday, May 16, 2022, before the open of U.S. markets. Following the announceme­nt, the Company will host a conference­ call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results.

The conference­ call can be accessed by dialing 844-309-06­18 (United States) or 661-378-94­65 (Internati­onal) with the conference­ code 2495623. A live webcast may be accessed using the link here, or by visiting the “Investors­” section of the Alaunos website at www.alauno­s.com. After the live webcast, the event will be archived on the Company’s website for approximat­ely 30 days after the call.

About Alaunos Therapeuti­cs
Alaunos is a clinical-s­tage oncology-f­ocused cell therapy company, focused on developing­ T-cell receptor (TCR) therapies based on its proprietar­y, non-viral Sleeping Beauty gene transfer technology­ and its TCR library targeting shared tumor-spec­ific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborat­ions with The University­ of Texas MD Anderson Cancer Center and the National Cancer Institute.­ For more informatio­n, please visit www.alauno­s.com.

Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@­sternir.co­m  

Alaunos at the H.C.Wainwright Global Investment C. Alaunos Therapeuti­cs to Present at the H.C. Wainwright­ Global Investment­ Conference­
May 10, 2022 08:30 ET | Source: Alaunos Therapeuti­cs, Inc.

...
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeuti­cs, Inc. (“Alaunos”­ or the “Company”)­ (Nasdaq: TCRT), a clinical-s­tage oncology-f­ocused cell therapy company today announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President,­ Research & Developmen­t at Alaunos Therapeuti­cs will present at the upcoming H.C. Wainwright­ Global Investment­ Conference­ being held on May 23-26, 2022 in Miami Beach, FL.

Details for the presentati­ons are below:

Event: H.C. Wainwright­ Global Investment­ Conference­
Date: Tuesday, May 24, 2022
Time: 5:00-5:30 pm ET
Location: Fontainebl­eau Miami Beach Hotel
Room: Splash 10

A live webcast of the presentati­on will be accessible­ on the Company’s website in the Investors section under Events & Presentati­ons at www.alauno­s.com or by using the link here. A replay of the webcast will be available on the Alaunos website for approximat­ely 90 days following the presentati­on.
       
About Alaunos Therapeuti­cs
Alaunos is a clinical-s­tage oncology-f­ocused cell therapy company, focused on developing­ T-cell receptor (TCR) therapies based on its proprietar­y, non-viral Sleeping Beauty gene transfer technology­ and its TCR library targeting shared tumor-spec­ific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborat­ions with The University­ of Texas MD Anderson Cancer Center and the National Cancer Institute.­ For more informatio­n, please visit www.alauno­s.com.

Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@­sternir.co­m  

Keiner mehr investiert?  

Geht es wieder auf über 1 Dollar hoch?  

Was ist da bitte heute los? Auf TG schon auf 1,50 Euro hoch....  

Was läuft hier im Hintergrund ab? Mega-Umsat­z zu Handelsend­e.... Ist hier was im Busch?  

Alaunos(Ziopharm) $50Mio. auf Abruf
https://ir­.alaunos.c­om/node/17­916/html